FDA raises questions over trial data of $2 million gene therapy drug
0
The FDA stopped short of pulling approval of Zolgensma, which treats children with spinal muscular atrophy.
The FDA stopped short of pulling approval of Zolgensma, which treats children with spinal muscular atrophy.